Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
CANbridge Pharmaceuticals, Inc. (1228.HK) reported its financial results for H1 2022, showcasing a revenue increase to RMB34.7 million, up RMB22.5 million from the prior year, largely driven by sales from Hunterase® and Nerlynx®. R&D expenses decreased to RMB158.3 million, leading to a reduced loss of RMB249.0 million. The company initiated three Phase II trials and announced positive Phase I results for CAN106, alongside advancements in its gene therapy platform. Upcoming milestones include potential NDA approval for CAN108 in H1 2023.
Connect Biopharma announced that it can conduct primary analysis of its pivotal trial for CBP-201, targeting moderate-to-severe atopic dermatitis, based on 255 enrolled patients. Top-line results are expected by year-end 2022, earlier than planned. The company aims to initiate pre-NDA discussions in 2024, targeting potential approval in China by 2025. The trial's secondary endpoints include EASI response rates, adding to the anticipation for CBP-201's efficacy against current treatments. The Phase 3 program timeline remains unchanged, with patient enrollment expected by late 2022.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) received notification from Nasdaq regarding a deficiency in its share price, which closed below $1.00 for thirty consecutive business days. The company has until December 13, 2022, to regain compliance with Nasdaq Listing Rule 5550(a)(2). If the share price closes above $1.00 for ten consecutive business days within this period, compliance will be achieved. The company may also be eligible for an additional compliance period if necessary, provided certain conditions are met.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei and CFO Steven Chan will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 am ET. A live webcast will be available on the Company’s Investor Relations page, with a replay post-event. Connect Biopharma focuses on therapies for chronic inflammatory diseases, leveraging T cell-driven research, including its lead product CBP-201 for treating atopic dermatitis and asthma. The company is advancing multiple candidates targeting T cell biology in the U.S. and China.
Connect Biopharma (Nasdaq: CNTB) will present data on CBP-201 at the Society for Investigative Dermatology Annual Conference from May 18-21, 2022. Preclinical experiments show CBP-201 effectively reduces Th2-driven inflammation biomarkers and exhibits a stronger binding affinity compared to dupilumab. The antibody targets interleukin-4 receptor alpha (IL-4Rα), with promising results from a Phase 2b clinical trial indicating potential for treating moderate-to-severe atopic dermatitis. The ongoing pivotal trial in China further supports its clinical significance.
CANbridge Pharmaceuticals has appointed Dr. Pauline Li as Senior Vice President of Clinical Development and Operations, effective May 8. Dr. Li previously held leadership roles at Connect Biopharma, overseeing significant clinical trial achievements. With a robust background in drug development across various markets, her experience is expected to enhance CANbridge's clinical programs targeting rare diseases and oncology. The company has three approved drugs and a pipeline of 11 assets, reflecting its commitment to addressing unmet medical needs.
Connect Biopharma (Nasdaq: CNTB) announced Phase 2 trial results for CBP-307, a treatment for ulcerative colitis. The 0.2 mg dosage showed a numerical decrease in the adapted Mayo Score at Week 12, but did not reach statistical significance (p=0.103). However, it achieved significant clinical remission rates compared to placebo: 28.3% vs. 9.6% (p=0.016). Lymphocyte count reductions confirmed pharmacodynamic activity. CBP-307 was generally well tolerated, with a 66% incidence of drug-related adverse events. The company is considering partnerships for further development while advancing lead candidate CBP-201.
Connect Biopharma reported financial results for the year ended December 31, 2021, highlighting a cash balance of RMB 1,706.9 million (USD 267.7 million). The company advanced its clinical development projects, announcing a Phase 3 trial for CBP-201 in atopic dermatitis set to start in H2 2022 and completion of enrollment for CBP-307's Phase 2 trial in ulcerative colitis. Research and development expenses surged to RMB 518.0 million (USD 81.2 million), contributing to a net loss of RMB 1,306.8 million (USD 205.0 million) for the year.
Connect Biopharma (NASDAQ: CNTB) has appointed Dr. Chin Lee as Chief Medical Officer, effective March 1, 2022, aiming to enhance its clinical pipeline for inflammatory diseases. Dr. Lee brings over 15 years of experience from Theravance Biopharma and Genentech, focusing on drug development in immunology. His expertise is expected to propel the advancement of their therapeutic candidates, including CBP-201 and CBP-307, which target conditions like asthma and ulcerative colitis. The company is committed to global clinical development and improving patient outcomes.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 4:20 PM ET. The chat will be accessible via a webcast on the company's Investor Relations page. Connect Biopharma is focused on developing therapies for chronic inflammatory diseases, with lead candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease.